Gary Patou, Director at Xenon Pharmaceuticals Inc. (XENE), sold 28,280 shares at $39.10 ($1.1M) on 2023-12-13, disclosed to the SEC on 2023-12-15.
Open-market sale of $1.1M XENE by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $38.94 | 5,100 | $199K | 17.6% |
| 2 | $39.10 | 2,303 | $90K | 8.0% |
| 3 | $39.10 | 2,303 | $90K | 8.0% |
| 4 | $39.68 | 577 | $23K | 2.0% |
| 5 | $39.68 | 1,167 | $46K | 4.1% |
| 6 | $39.68 | 1,278 |
| $51K |
| 4.5% |
| 7 | $39.84 | 3,977 | $158K | 14.1% |
| 8 | $39.84 | 3,977 | $158K | 14.1% |
| 9 | $41.05 | 7,598 | $312K | 27.7% |
| Total | $39.87 avg | 28,280 | $1.1M | 100% |
| Filing → |
| XENE | SELL | 2023-12-15 | $624K | — | Filing → |
| XENE | SELL | 2022-11-28 | $276K | — | Filing → |
| XENE | BUY | 2017-08-14 | $21K | — | Filing → |